Back

How potassium binders can enable RAASi therapy in heart failure.

27 August 2022 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) Open Access ESC Congress 2022

About the speaker

Photo
Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

4 More presentations in this session

Presentation thumbnail
Clinical case presentation of a patient with heart failure.
Professor P. Van Der Meer (Groningen, NL)
Slides Video
Presentation thumbnail
The importance of optimal RAASi therapy in heart failure.
Professor D. Atar (Oslo, NO)
Slides Video
Presentation thumbnail
Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure.
Doctor C. Bonanad Lozano (Valencia, ES)
Slides Video
Presentation thumbnail
Panel discussion.
Professor P. Van Der Meer (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 13:05 CET
You may be interested in
thumbnail
Congress Presentation
The promise of novel potassium binders to optimize RAASi therapy.
22 May 2022
thumbnail
Congress Presentation
Summary and conclusions
26 August 2023
thumbnail
Congress Presentation
Potassium binding as RAASi enabling therapy: applying recent insights into practice.
21 May 2022
thumbnail
Congress Session
Practice-changing studies from NEJM 2022-2023
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources